Literature DB >> 10213653

Racial differences in bone mineral density and bone loss among end-stage renal disease patients.

C O Stehman-Breen1, D Sherrard, A Walker, R Sadler, A Alem, J Lindberg.   

Abstract

Although black patients without end-stage renal disease (ESRD) have a greater bone mineral density (BMD) than whites, the impact of race on BMD among patients with ESRD who are likely to have varying degrees of renal osteodystrophy is not known. We undertook a cohort study of 106 hemodialysis patients comparing BMD and bone loss between black and white patients with ESRD to determine if black patients have a greater BMD and less bone loss than white patients with ESRD. BMD was determined by dual-energy radiograph absorptiometry (DEXA). Osteopenia was defined as greater than 1 standard deviation (SD) less than the mean of peak bone mass (T score <-1), and osteoporosis was defined as greater than 2.5 SDs less than the mean of peak bone mass (T score <-2.5). The association between BMD and race was estimated using linear regression. The risk for osteopenia among black compared with white patients was calculated using logistic regression. Black patients were similar to white patients with respect to all characteristics noted, except black patients were less likely to be men (69.7% v 49. 4%) and tended to have greater intact parathyroid hormone (PTH) values (mean, 403.2 +/- 384.5 pg/mL v 161.4 +/- 129.0 pg/mL). Compared with whites, the BMD of blacks was a mean of 1.15 (95% confidence interval [CI], 0.54 to 1.78) SDs greater at the femoral neck after adjusting for age, PTH level, and sex. The percentage of bone loss per year was similar between blacks and whites. The risk for osteopenia among blacks was significantly less than that among whites (odds ratio = 0.15; 95% CI, 0.04 to 0.59) after adjusting for age, sex, and PTH level. Black patients with ESRD have a greater BMD and are at decreased risk for osteopenia compared with whites, independent of renal osteodystrophy. When considering bone disease among patients with ESRD, physicians should also consider osteoporosis and the impact of race on BMD.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10213653     DOI: 10.1016/s0272-6386(99)70430-0

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  19 in total

1.  Bone mineral density and its correlation with clinical and laboratory factors in chronic peritoneal dialysis patients.

Authors:  Fettah Fevzi Ersoy; Stauros Ploumis Passadakis; Paul Tam; Evaggelos Dimitros Memmos; Pericles Konstantinos Katopodis; Cetin Ozener; Fehmi Akçiçek; Taner Camsari; Kenan Ateş; Rezzan Ataman; John George Vlachojannis; Athanasios Nicholas Dombros; Cengiz Utaş; Tekin Akpolat; Semra Bozfakioğlu; George Wu; Ibrahim Karayaylali; Turgay Arinsoy; Panagiotis Charalampos Stathakis; Mahmut Yavuz; John Dimitrios Tsakiris; Chrysostomos Athanasios Dimitriades; Mehmet Emin Yilmaz; Meral Gültekin; Binnur Karayalçin; Mehmet Yardimsever; Dimitrios George Oreopoulos
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

2.  Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD.

Authors:  Csaba P Kovesdy; Vitalie Ureche; Jun L Lu; Kamyar Kalantar-Zadeh
Journal:  Nephrol Dial Transplant       Date:  2010-03-17       Impact factor: 5.992

Review 3.  Hemodialysis Disparities in African Americans: The Deeply Integrated Concept of Race in the Social Fabric of Our Society.

Authors:  Keith C Norris; Sandra F Williams; Connie M Rhee; Susanne B Nicholas; Csaba P Kovesdy; Kamyar Kalantar-Zadeh; L Ebony Boulware
Journal:  Semin Dial       Date:  2017-03-09       Impact factor: 3.455

Review 4.  Gonadal dysfunction in chronic kidney disease.

Authors:  Biff F Palmer; Deborah J Clegg
Journal:  Rev Endocr Metab Disord       Date:  2017-03       Impact factor: 6.514

5.  Loss of bone mineral density and trabecular bone score in elderly hemodialysis patients: a 2-year follow-up, prospective, single-centre study.

Authors:  Ludmila Brunerová; Petr Kasalický; Jana Verešová; Renata Lažanská; Jana Potočková; Ivan Rychlík
Journal:  Int Urol Nephrol       Date:  2020-02-03       Impact factor: 2.370

6.  Osteoporosis and cardiovascular disease: lessons from chronic kidney disease.

Authors:  Keith A Hruska; Suresh Mathew; Richard Lund
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

7.  Beneficial role of intravenous calcitriol on bone mineral density in children with severe secondary hyperparathyroidism.

Authors:  Esra Baskin; Seza Ozen; Musturay Karçaaltincaba; Nesrin Besbas; Umit Saatci; Ali Düzova; Pinar Isik Agras; Mithat Haliloglu; Aysin Bakkaloglu
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

Review 8.  Hyperphosphatemia of chronic kidney disease.

Authors:  Keith A Hruska; Suresh Mathew; Richard Lund; Ping Qiu; Raymond Pratt
Journal:  Kidney Int       Date:  2008-04-30       Impact factor: 10.612

9.  Correlations between serum testosterone, estradiol, and sex hormone-binding globulin and bone mineral density in a diverse sample of men.

Authors:  Andre B Araujo; Thomas G Travison; Benjamin Z Leder; John B McKinlay
Journal:  J Clin Endocrinol Metab       Date:  2008-03-25       Impact factor: 5.958

Review 10.  Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD).

Authors:  Keith A Hruska; Eric T Choi; Imran Memon; T Keefe Davis; Suresh Mathew
Journal:  Pediatr Nephrol       Date:  2009-11-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.